Identifying core gene modules in glioblastoma based on multilayer factor-mediated dysfunctional regulatory networks through integrating multi-dimensional genomic data

The driver genetic aberrations collectively regulate core cellular processes underlying cancer development. However, identifying the modules of driver genetic alterations and characterizing their functional mechanisms are still major challenges for cancer studies. Here, we developed an integrative multi-omics method CMDD to identify the driver modules and their affecting dysregulated genes through characterizing genetic alteration-induced dysregulated networks. Applied to glioblastoma (GBM), the CMDD identified a core gene module of 17 genes, including seven known GBM drivers, and their dysregulated genes. The module showed significant association with shorter survival of GBM. When classifying driver genes in the module into two gene sets according to their genetic alteration patterns, we found that one gene set directly participated in the glioma pathway, while the other indirectly regulated the glioma pathway, mostly, via their dysregulated genes. Both of the two gene sets were significant contributors to survival and helpful for classifying GBM subtypes, suggesting their critical roles in GBM pathogenesis. Also, by applying the CMDD to other six cancers, we identified some novel core modules associated with overall survival of patients. Together, these results demonstrate integrative multi-omics data can identify driver modules and uncover their dysregulated genes, which is useful for interpreting cancer genome.

[1]  A. G. de la Fuente From 'differential expression' to 'differential networking' - identification of dysfunctional regulatory networks in diseases. , 2010, Trends in genetics : TIG.

[2]  D. Pe’er,et al.  An Integrated Approach to Uncover Drivers of Cancer , 2010, Cell.

[3]  R. Nahta,et al.  P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer. , 2013, Current medicinal chemistry.

[4]  Xia Li,et al.  Prioritizing cancer-related key miRNA–target interactions by integrative genomics , 2012, Nucleic acids research.

[5]  Manu Setty,et al.  Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma , 2012, Molecular systems biology.

[6]  H. Katagiri,et al.  ESR1 gene amplification in endometrial carcinomas: a clinicopathological analysis. , 2013, Anticancer research.

[7]  Peter A. Jones,et al.  Cancer genetics and epigenetics: two sides of the same coin? , 2012, Cancer cell.

[8]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[9]  Bradley P. Coe,et al.  DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers , 2008, Oncogene.

[10]  Harald Martens,et al.  Analysis of genetic marker-phenotype relationships by jack-knifed partial least squares regression (PLSR). , 2004, Hereditas.

[11]  G. Pfeifer,et al.  Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. , 2010, Advances in genetics.

[12]  Li Wang,et al.  IndividualizedPath: identifying genetic alterations contributing to the dysfunctional pathways in glioblastoma individuals. , 2014, Molecular bioSystems.

[13]  J. Sarkaria,et al.  EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180 , 2014, Oncogene.

[14]  Torbjörn E. M. Nordling,et al.  Network modeling of the transcriptional effects of copy number aberrations in glioblastoma , 2011, Molecular systems biology.

[15]  Marcel J. T. Reinders,et al.  Identification of Networks of Co-Occurring, Tumor-Related DNA Copy Number Changes Using a Genome-Wide Scoring Approach , 2010, PLoS Comput. Biol..

[16]  Tongbin Li,et al.  miRecords: an integrated resource for microRNA–target interactions , 2008, Nucleic Acids Res..

[17]  G. Hong,et al.  Nucleic Acids Research , 2015, Nucleic Acids Research.

[18]  Xin Chen,et al.  TRANSFAC: an integrated system for gene expression regulation , 2000, Nucleic Acids Res..

[19]  Jan Koster,et al.  Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. , 2008, Cancer research.

[20]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[21]  Eli Upfal,et al.  De Novo Discovery of Mutated Driver Pathways in Cancer , 2011, RECOMB.

[22]  H. Kluger,et al.  Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies , 2012, Current Oncology Reports.

[23]  J. Stockman,et al.  A Network Model of a Cooperative Genetic Landscape in Brain Tumors , 2011 .

[24]  A. Bashashati,et al.  DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer , 2012, Genome Biology.

[25]  M. Núñez,et al.  Abrogation of the p38 MAPK α signaling pathway does not promote radioresistance but its activity is required for 5-Fluorouracil-associated radiosensitivity. , 2013, Cancer letters.

[26]  David L. Masica,et al.  Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. , 2011, Cancer research.

[27]  Robert Tibshirani,et al.  A network model of a cooperative genetic landscape in brain tumors. , 2009, JAMA.

[28]  L. Deangelis,et al.  Glioblastoma: molecular analysis and clinical implications. , 2013, Annual review of medicine.

[29]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[30]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[31]  Shi-Hua Zhang,et al.  Identifying multi-layer gene regulatory modules from multi-dimensional genomic data , 2012, Bioinform..

[32]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[33]  Ivan Smirnov,et al.  Clinical Stratification of Glioblastoma Based on Alterations in Retinoblastoma Tumor Suppressor Protein (RB1) and Association With the Proneural Subtype , 2012, Journal of neuropathology and experimental neurology.

[34]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[35]  Paul A. Bates,et al.  Global topological features of cancer proteins in the human interactome , 2006, Bioinform..

[36]  Giovanni Tesoriere,et al.  RB1 in cancer: Different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis , 2013, Journal of cellular physiology.

[37]  Teresa M. Przytycka,et al.  Identifying Causal Genes and Dysregulated Pathways in Complex Diseases , 2011, PLoS Comput. Biol..

[38]  M. Berger,et al.  The p38 Mitogen-Activated Protein Kinase Pathway Links the DNA Mismatch Repair System to the G2 Checkpoint and to Resistance to Chemotherapeutic DNA-Methylating Agents , 2003, Molecular and Cellular Biology.

[39]  Richard Simon,et al.  Identifying cancer driver genes in tumor genome sequencing studies , 2011, Bioinform..

[40]  Yun Xiao,et al.  Identifying dysfunctional miRNA-mRNA regulatory modules by inverse activation, cofunction, and high interconnection of target genes: a case study of glioblastoma. , 2013, Neuro-oncology.

[41]  Nicholas T. Ingolia,et al.  Mammalian microRNAs predominantly act to decrease target mRNA levels , 2010, Nature.

[42]  Cathie Garnis,et al.  Genetic alteration and gene expression modulation during cancer progression , 2004, Molecular Cancer.

[43]  Mark D. Johnson,et al.  Numb Regulates Glioma Stem Cell Fate and Growth by Altering Epidermal Growth Factor Receptor and Skp1‐Cullin‐F‐Box Ubiquitin Ligase Activity , 2012, Stem cells.

[44]  A. Frigessi,et al.  Principles and methods of integrative genomic analyses in cancer , 2014, Nature Reviews Cancer.

[45]  L. Zender,et al.  Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles , 2014, Nature.

[46]  P. Kleihues,et al.  Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.

[47]  D. Valle,et al.  Online Mendelian Inheritance In Man (OMIM) , 2000, Human mutation.

[48]  E. Haralambieva,et al.  BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFN&ggr;–STAT1–IRF1–p53 axis in diffuse large B-cell lymphoma , 2013, Journal of Cell Science.

[49]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[50]  J. Gutkind,et al.  A role for p38 MAPK in head and neck cancer cell growth and tumor‐induced angiogenesis and lymphangiogenesis , 2014, Molecular oncology.

[51]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[52]  S. Chandna,et al.  Connexin-43 regulates p38-mediated cell migration and invasion induced selectively in tumour cells by low doses of γ-radiation in an ERK-1/2-independent manner. , 2014, Carcinogenesis.

[53]  G. Reifenberger,et al.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.

[54]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[55]  C. Sander,et al.  Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.

[56]  S. Kellouche,et al.  Cell cycle arrest or survival signaling through αv integrins, activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids. , 2014, Experimental cell research.

[57]  Roded Sharan,et al.  Simultaneous Identification of Multiple Driver Pathways in Cancer , 2013, PLoS Comput. Biol..

[58]  J. Olson,et al.  p38 MAP kinase: a convergence point in cancer therapy. , 2004, Trends in molecular medicine.

[59]  Shi-Hua Zhang,et al.  Detecting disease associated modules and prioritizing active genes based on high throughput data , 2010, BMC Bioinformatics.

[60]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[61]  R. Carpenter,et al.  STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation With STAT3 , 2013, Molecular carcinogenesis.

[62]  D. Gutmann,et al.  Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. , 2003, Cancer research.

[63]  C. Print,et al.  Cell Cycle Gene Networks Are Associated with Melanoma Prognosis , 2012, PloS one.

[64]  Bin Fang,et al.  Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms , 2013, Molecular systems biology.

[65]  J. V. van Deursen,et al.  Aneuploidy in health, disease, and aging , 2013, The Journal of cell biology.

[66]  Peter Nürnberg,et al.  Distinct methylation profiles of glioma subtypes , 2003, International journal of cancer.

[67]  A. Lykkesfeldt,et al.  Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling , 2013, Breast Cancer Research and Treatment.

[68]  K. Becker,et al.  The Genetic Association Database , 2004, Nature Genetics.

[69]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..